Vandetanib (Caprelsa, Astra Zeneca Pharmaceuticals) is an orally bioavailable multi-RTK (receptor Tyrosine kinase) inhibitor that blocks the mutant RET gene product and has anti-tumor activity in adults with hereditary MTC [10, 11]. Here, RET is linked to medullary thyroid gland carcinoma.